Fraxinus Velutina Pollen

Dosage for Fraxinus Velutina Pollen is highly individualized and must be determined by an allergist based on the patient's sensitivity level. There is no 'one size fits all' dose.

For Diagnostic Testing

• Prick-Puncture Method: Typically uses a 1:10 or 1:20 w/v concentration. A single drop is applied to the skin, and the skin is pricked. Results are read after 15–20 minutes.
• Intradermal Method: If prick tests are negative, a more sensitive intradermal test using a much more dilute solution (e.g., 100 PNU/mL to 1,000 PNU/mL) may be used.

For Immunotherapy

Immunotherapy follows two distinct phases:

1. 1Build-up Phase: This phase involves weekly or bi-weekly injections. The starting dose is usually very low (e.g., 0.05 mL of a 1:10,000 w/v dilution). The dose is gradually increased every week by 0.05 mL to 0.1 mL until the maintenance dose is reached. This phase typically lasts 3 to 6 months.
2. 2Maintenance Phase: Once the effective dose is reached (often 0.5 mL of a 1:100 or 1:20 w/v concentration), the frequency of injections is decreased to once every 2 to 4 weeks. Maintenance therapy is generally continued for 3 to 5 years to ensure long-term desensitization.

Fraxinus Velutina Pollen is used in children, but the safety and efficacy are closely tied to the child's ability to tolerate the injections and the risk of systemic reactions. Pediatric dosing follows the same build-up and maintenance principles as adult dosing, though healthcare providers may use smaller volume increments for very young or highly sensitive children. There is no specific age cutoff, but most specialists wait until a child is at least 5 years old to ensure they can communicate symptoms of a systemic reaction.

Renal Impairment

No specific dose adjustments are required for patients with kidney disease, as the extract is not cleared primarily by the kidneys in a way that affects toxicity. However, the patient's overall health must be stable.

Hepatic Impairment

No dose adjustments are necessary for patients with liver impairment.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. If an elderly patient experiences a systemic reaction, they may be less able to tolerate the stress of anaphylaxis or the administration of epinephrine.

This medication is NEVER self-administered at home. It must be given via subcutaneous injection (usually in the back of the upper arm) in a medical facility.

• Preparation: The skin is cleaned with alcohol. The injection is given into the fatty tissue, avoiding muscle or blood vessels.
• Observation: Patients MUST remain in the doctor's office for at least 30 minutes after every injection. Most fatal or near-fatal reactions occur within this window.
• Storage: Vials must be kept refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. If the extract becomes cloudy or changes color, it should not be used.

If a dose is missed during the build-up phase, the next dose may need to be reduced to ensure safety. If multiple doses are missed, the healthcare provider may need to restart the build-up from a lower concentration. During the maintenance phase, a missed dose usually requires a slight reduction in the next dose if the interval has been too long.

An overdose of allergenic extract usually manifests as an immediate systemic allergic reaction. Signs include:

• Severe hives (urticaria)
• Swelling of the throat or tongue
• Difficulty breathing or wheezing
• Rapid drop in blood pressure (shock)
• Loss of consciousness

In the event of an overdose, epinephrine is the primary treatment, followed by antihistamines, corticosteroids, and emergency supportive care.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Always inform your doctor if you feel unwell on the day of your injection.

Most patients receiving Fraxinus Velutina Pollen immunotherapy will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Local Swelling: A raised, red area at the injection site (often called a 'local'). If the swelling is smaller than a half-dollar (about 3 cm), it is considered normal.
• Itching (Pruritus): Intense itching at the site of the injection which usually resolves within a few hours.
• Redness (Erythema): A warm, red patch around the injection area.
• Tenderness: The arm may feel sore or heavy for 24 to 48 hours after the shot.

These reactions are more significant and may require a dosage adjustment for the next visit.

• Large Local Reactions: Swelling that exceeds 5–10 cm in diameter. These can be delayed, appearing 6–12 hours after the injection.
• Fatigue: Some patients report feeling unusually tired for the remainder of the day after an injection.
• Mild Nasal Congestion: A slight increase in hay fever symptoms shortly after treatment.

• Generalized Hives: Itchy bumps appearing on parts of the body far from the injection site.
• Mild Wheezing: A slight tightening of the chest, particularly in patients with a history of asthma.
• Nausea: Feeling sick to the stomach or experiencing mild abdominal cramping.

> Warning: Stop taking Fraxinus Velutina Pollen and call your doctor immediately if you experience any of these. These symptoms indicate anaphylaxis, a life-threatening emergency.

• Angioedema: Rapid swelling of the lips, tongue, or throat that can block the airway.
• Dyspnea and Bronchospasm: Severe shortness of breath, gasping, or a high-pitched whistling sound when breathing.
• Hypotension: A sudden drop in blood pressure, which may feel like dizziness, lightheadedness, or 'blacking out'.
• Tachycardia: A racing heart or palpitations.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.
• Uterine Contractions: In pregnant women, systemic reactions can trigger uterine activity.

There are no known long-term 'toxic' effects of Fraxinus Velutina Pollen on organs like the liver or kidneys. The primary long-term effect is the intended modification of the immune system. However, patients may develop a persistent 'nodule' (a small, hard lump) at the injection site if injections are given in the same spot too frequently. This is usually a benign accumulation of inflammatory cells or aluminum (if an aluminum-adsorbed extract is used).

Fraxinus Velutina Pollen, like all allergenic extracts, carries a significant warning regarding the risk of severe systemic reactions. While not always formatted as a 'Black Box' on every individual vial, the FDA-approved class labeling for allergenic extracts emphasizes:

1. 1Anaphylaxis Risk: This product can cause life-threatening allergic reactions.
2. 2Supervision Required: It must only be administered by healthcare professionals trained in the management of anaphylaxis.
3. 3Patient Stability: It should not be administered to patients with unstable or severe asthma, as they are at the highest risk for fatal outcomes.
4. 4Observation Period: Patients must be observed for at least 30 minutes post-injection.

Report any unusual symptoms to your healthcare provider. Even a 'large' local reaction should be reported, as it may predict a future systemic reaction.

Fraxinus Velutina Pollen is a potent biological product. Safety is paramount, and several factors must be considered before each injection. Patients should be in their 'baseline' state of health. If a patient is suffering from an acute infection, a fever, or an exacerbation of their asthma, the injection should be postponed. The immune system is already 'primed' during these times, and adding an allergen extract can increase the risk of a systemic reaction.

No FDA black box warnings for Fraxinus Velutina Pollen exist in the same format as high-risk oral medications; however, the Class Warning for Allergenic Extracts is equivalent in severity. It states that allergenic extracts are capable of producing severe systemic reactions, including death, in highly sensitive individuals. The warning specifically highlights that patients with unstable asthma or those taking beta-blockers are at significantly increased risk.

• Allergic Reactions / Anaphylaxis Risk: The primary risk is a systemic IgE-mediated reaction. This is more common during the build-up phase or when switching to a new vial of extract (which may be more potent than the previous, aged vial).
• Asthma Status: Patients with symptomatic or poorly controlled asthma should not receive immunotherapy. A peak flow meter may be used before the injection to ensure the patient's lung function is within their normal range.
• Cardiovascular Disease: Patients with pre-existing heart conditions are at higher risk if they experience anaphylaxis, as the stress on the heart and the need for epinephrine can complicate their condition.
• Injection Technique: The extract must be given subcutaneously. Accidental intramuscular or intravenous injection can lead to rapid systemic absorption and immediate anaphylaxis.

There are no standard laboratory tests (like blood counts) required for monitoring Fraxinus Velutina Pollen therapy. Instead, monitoring is clinical:

• Immediate Observation: Vital signs and lung sounds may be checked if the patient feels unwell after the shot.
• Peak Flow Monitoring: For asthmatic patients, measuring the Peak Expiratory Flow Rate (PEFR) before and after injections is common practice.
• Reaction Log: Patients are often asked to keep a log of any delayed swelling or symptoms that occur after they leave the office.

Generally, Fraxinus Velutina Pollen does not cause sedation. However, if a patient experiences a systemic reaction or is given antihistamines/epinephrine to treat a reaction, they should not drive or operate machinery until they are fully recovered and cleared by a physician.

Alcohol should be avoided on the day of the injection. Alcohol can cause vasodilation (widening of the blood vessels), which may theoretically increase the rate of allergen absorption from the injection site and potentially worsen an allergic reaction.

Immunotherapy is a long-term commitment. If a patient decides to stop treatment, there is no 'withdrawal' syndrome. However, the allergic symptoms are likely to return over time as the immune system's tolerance fades. If treatment is paused for more than a few weeks, it cannot be resumed at the same dose; a 'step-back' in dosage is required to ensure safety.

> Important: Discuss all your medical conditions with your healthcare provider before starting Fraxinus Velutina Pollen. Be sure to mention if you have started any new heart or blood pressure medications.

• Beta-Blockers (Non-selective and Selective): Drugs like propranolol, metoprolol, or even beta-blocker eye drops (timolol) are generally considered a contraindication for immunotherapy. The reason is twofold: first, beta-blockers can make an allergic reaction more severe; second, and more importantly, they block the effects of epinephrine (adrenaline). If a patient on a beta-blocker has anaphylaxis, the standard life-saving treatment (epinephrine) may not work effectively, leading to a potentially fatal outcome.

• ACE Inhibitors: Medications like lisinopril or enalapril, used for blood pressure, have been associated with an increased risk of more severe systemic reactions to allergenic extracts. This may be due to the inhibition of the breakdown of bradykinin, a substance involved in inflammation and swelling.
• MAO Inhibitors (MAOIs): Drugs like phenelzine used for depression can potentiate the effects of epinephrine, which might be used to treat a reaction, leading to a dangerous spike in blood pressure.

• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs like amitriptyline can increase the body's sensitivity to epinephrine, requiring cautious use of emergency medications.
• Other Immunotherapy: If a patient is receiving multiple types of immunotherapy (e.g., for food or venom), the timing must be coordinated to avoid overloading the immune system on a single day.

• Alcohol: As mentioned previously, alcohol can increase blood flow to the skin and potentially speed up the absorption of the allergen, increasing the risk of a reaction.
• Large Meals: It is generally recommended not to eat a very heavy meal immediately before or after an injection, as gastrointestinal symptoms of anaphylaxis (cramping, vomiting) can be confused with simple indigestion.

• St. John's Wort: While no direct interaction with the pollen exists, St. John's Wort can affect how the body processes many medications. Its effect on immunotherapy is unknown but should be reported.
• Feverfew or Ginkgo: These can have mild blood-thinning effects; while they don't interact with the pollen, they might slightly increase the risk of bruising at the injection site.

• Skin Tests: Taking antihistamines (like cetirizine, loratadine, or diphenhydramine) will suppress the 'wheal and flare' reaction, leading to a false-negative result. Patients must stop antihistamines for 3 to 7 days before skin testing.
• Serum IgE Tests: Immunotherapy will eventually lead to changes in serum IgE and IgG4 levels, which is the intended effect, but this must be interpreted by an allergist.

| Interaction Category | Management Strategy |

|---|---|

| Beta-Blockers | Switch to an alternative blood pressure medication if possible. |

| Antihistamines | Discontinue 72-96 hours before diagnostic skin testing. |

| ACE Inhibitors | Monitor closely; consider risk vs. benefit of immunotherapy. |

| Epinephrine | Be aware that TCAs/MAOIs may potentiate the pressor effect. |

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even over-the-counter eye drops or cold medicines can be relevant.

Fraxinus Velutina Pollen must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients with a Forced Expiratory Volume in 1 second (FEV1) consistently below 70% of predicted, or those with frequent acute exacerbations, are at an unacceptably high risk of a fatal bronchial reaction to the injection.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The cardiovascular system must be stable enough to handle the potential stress of a systemic reaction and the administration of epinephrine.
3. 3Hypersensitivity to Excipients: If a patient has a known severe allergy to glycerin or phenol (used as a preservative in the vials), they cannot receive the extract.
4. 4Inability to Communicate: Patients who cannot report symptoms of an early reaction (e.g., certain severe neurological conditions) should not receive immunotherapy because the safety of the treatment relies on patient feedback during the 30-minute observation period.

These conditions require a careful risk-benefit analysis by the allergist:

• Beta-Blocker Therapy: While often listed as absolute, some specialists may proceed with extreme caution if no other blood pressure medication is effective, though this is rare.
• Autoimmune Disorders: There is a theoretical concern that stimulating the immune system with pollen extracts could worsen conditions like Lupus or Rheumatoid Arthritis, though clinical evidence for this is limited.
• Malignancy: Patients undergoing active chemotherapy or with advanced cancer may have unpredictable immune responses.
• Pregnancy (Starting Therapy): Immunotherapy should generally not be started during pregnancy due to the risk of anaphylaxis-induced fetal hypoxia (lack of oxygen).

Patients allergic to Fraxinus Velutina Pollen often show cross-reactivity with other members of the Oleaceae family. This includes:

• Other Ash Trees: White Ash (Fraxinus americana) and Green Ash (Fraxinus pennsylvanica).
• Olive Trees: Olea europaea.
• Privet and Forsythia: Common landscaping shrubs.

If a patient is highly sensitive to one of these, they may react more strongly to the Velvet Ash extract during testing.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Fraxinus Velutina Pollen. Always provide a full list of your allergies and past reactions to medications.

Fraxinus Velutina Pollen is classified as FDA Pregnancy Category C. This means there are no adequate and well-controlled studies in pregnant women.

• Risk Summary: The primary risk during pregnancy is not the extract itself, but the potential for a systemic reaction (anaphylaxis). Anaphylaxis in the mother can cause a sudden drop in blood pressure, leading to placental insufficiency and fetal distress or death.
• Clinical Practice: Allergists generally do not start new immunotherapy build-up during pregnancy. However, if a woman is already on a stable maintenance dose and is tolerating it well, the treatment is often continued, as the risk of a reaction is much lower during maintenance.

It is not known whether the protein components of Fraxinus Velutina Pollen are excreted in human milk. However, because these are large proteins that are degraded at the injection site, it is highly unlikely that they would reach the infant in significant amounts through breastfeeding. The consensus in the allergy community is that immunotherapy is safe for nursing mothers.

Allergen immunotherapy is widely used in the pediatric population.

• Efficacy: Studies show that immunotherapy can not only reduce current symptoms but may also prevent the development of new allergies and reduce the risk of the 'allergic march' (the progression from hay fever to asthma).
• Safety: Children should be old enough to cooperate with the injection process and, more importantly, to describe symptoms like an itchy throat or 'feeling funny,' which could signal a reaction.

In patients over 65, the decision to use Fraxinus Velutina Pollen must be made with caution.

• Cardiovascular Risk: Older adults are more likely to have underlying heart disease or be taking medications like beta-blockers or ACE inhibitors, both of which increase the risk of immunotherapy.
• Benefit: If an older adult has clear IgE-mediated disease that is significantly impacting their quality of life, immunotherapy can be very effective, provided their cardiovascular health is stable.

There are no specific guidelines for the use of allergenic extracts in patients with renal impairment. Because the extract is composed of natural proteins that are broken down by proteases, renal clearance is not a limiting factor for dosing. However, if the patient has end-stage renal disease, their overall physiological fragility may increase the risk of complications from a systemic reaction.

Liver disease does not affect the metabolism of Fraxinus Velutina Pollen extracts. No dose adjustments are required for patients with cirrhosis or other hepatic conditions, provided they are hemodynamically stable.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant or develop new health problems during the course of your treatment.

Fraxinus Velutina Pollen extract acts as an immunomodulator. In an allergic individual, exposure to the proteins in the pollen (such as the major allergen Fra v 1) triggers a Type I hypersensitivity reaction. The extract works by introducing these same allergens in a controlled, subcutaneous manner.

At the molecular level, the extract interacts with dendritic cells, which present the allergens to T-cells. Immunotherapy induces the production of regulatory T-cells (Tregs) that produce IL-10. IL-10 is a critical cytokine that suppresses IgE production and instead promotes the production of IgG4. IgG4 acts as a 'decoy' or 'blocking' antibody; it binds to the pollen allergens before they can reach the IgE on the surface of mast cells, thereby preventing the release of histamine.

• Dose-Response: There is a clear dose-response relationship in immunotherapy. Higher maintenance doses (within safety limits) generally result in better long-term symptom control and more significant changes in antibody levels.
• Onset of Effect: The clinical effects are not immediate. Most patients begin to notice a reduction in symptoms toward the end of the build-up phase (3-6 months), with maximum benefit usually seen after 12-18 months of maintenance therapy.
• Duration of Effect: One of the unique aspects of this therapy is its 'disease-modifying' potential. After 3-5 years of treatment, the immune system often remains tolerant to the pollen for several years after the injections are stopped.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous localized absorption) |

| Protein Binding | N/A (Biological proteins) |

| Half-life | Hours (for protein degradation) |

| Tmax | 30-60 minutes (for local absorption) |

| Metabolism | Local and systemic proteolysis |

| Excretion | Renal (as amino acids/peptides) |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides derived from the pollen of Fraxinus velutina.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for various allergenic fractions.
• Solubility: Highly soluble in aqueous buffered solutions or 50% glycerin.
• Structure: The allergens are globular proteins. Fra v 1, the major allergen, is a member of the 'Ole e 1-like' protein family.

Fraxinus Velutina Pollen is classified as a Non-Standardized Pollen Allergenic Extract. It is part of the broader therapeutic category of Allergen Immunotherapy Agents. Related medications include other tree pollen extracts (e.g., Oak, Elm, Maple) and standardized extracts like Short Ragweed or Timothy Grass.